A Phase II, Open‐Label Study of the Efficacy and Safety of Imiquimod in the Treatment of Superficial and Mixed Infantile Hemangioma

Abstract

Treatment of infants with infantile hemangioma with imiquimod up to seven times per week for 16 weeks was generally well tolerated with low systemic exposure. Improvement was observed in hemangioma coloration, but not lesion size, suggesting effects were limited to the superficial component.